Study of ATPase and GTPase levels in Fibrotic Lung Disease with and without COVID-19 Vaccination

Background: In eukaryotic cells, the acidification of intracellular compartments is the responsibility of vacuolar H+ ATPase, a family of proton pumps, sometimes known as V-ATPases. Small GTPases are signaling molecules that regulate important cellular processes as well as subcellular activities making them essential players, particularly in a wide variety of coronavirus infection processes. Objectives: The purpose of this research was to assess the levels of ATPase and GTPase in fibrotic lung disease patients who had received or had not received the COVID-19 vaccination, and then to compare these levels with those of the control group. Methods: A total of 150 individuals participated in this study, divided into three groups. The first group was the control group (N=50). In the second group (N=50) patients with fibrotic lung disease () who did not get the COVID-19 vaccination. Fifty patients who had received the COVID-19 vaccination made up the third group ()(N=50). Enzyme-linked immunosorbent assay was the method that was used to determine the amounts of ATPase and GTPase. The P- P-value of 0.05 or less is considered statistically significant. ROC tests were examined for ATPase and GTPase.      Results: The data analysis reported a significant rise in alkaline phosphatase, Alanine aminotransferase, and Aspartate-aminotransferase  () among the three groups. Both ATPase and GTPase levels were shown to have significantly increased in Groups 3 and 2 as compared to Group 1 levels. Moreover, a substantial rise was discovered in Group 3  in comparison to Group 2 which was detected. Conclusion: ATPase and GTPase levels are increased in patients with fibrotic lung disease regardless of the COVID-19 vaccination state.